

CONSOLIDATED STATEMENTS OF INCOME

Mitsubishi Tanabe Pharma Corporation and Consolidated Subsidiaries
Years ended March 31, 2010 and 2009

	Millions of yen		Thousands of U.S. dollars (Note 1)
	2010	2009	2010
Net sales (Note 22)	¥404,747	¥414,752	\$4,350,247
Cost of sales	147,800	158,184	1,588,564
Gross profit	256,947	256,568	2,761,683
Selling, general and administrative expenses (Note 14)	195,472	184,874	2,100,946
Operating income (Note 22)	61,475	71,694	660,737
Other income (expenses):			
Interest and dividend income	2,515	2,988	27,031
Interest expense	(25)	(87)	(269)
Foreign exchange loss	(1,452)	(443)	(15,606)
Donations	(360)	(399)	(3,869)
Loss on sales or disposal of property, plant and equipment, net	(459)	(958)	(4,933)
Gain on sales of investments in securities, net	85	144	913
Subsidies for establishing a business	-	400	-
Compensation received	-	489	-
Loss related to business suspension (Note 15)	(3,296)	-	(35,426)
Provision of reserve for HCV litigation (Note 24)	(3,000)	(8,800)	(32,244)
Loss on valuation of investments in securities	(233)	(6,635)	(2,504)
Special retirement benefits (Note 9)	(23)	(4,344)	(247)
Impairment loss (Note 16)	(1,837)	(3,351)	(19,744)
Settlement for USA HIV litigation	-	(1,256)	-
Loss on product recall	-	(657)	-
Loss on shutdown of a plant	-	(164)	-
Restructuring loss	(1,583)	(342)	(17,014)
Other, net	(833)	(293)	(8,953)
	(10,501)	(23,708)	(112,865)
Income before income taxes and minority interests	50,974	47,986	547,872
Income taxes (Note 10):			
Current	24,841	27,409	266,993
Deferred	(2,796)	(6,355)	(30,052)
	22,045	21,054	236,941
Minority interests	(1,324)	400	(14,230)
Net income	¥ 30,253	¥ 26,532	\$ 325,161

See accompanying notes to consolidated financial statements.